Journal of Oncology Pharmacy Practice最新文献

{"title":"Palonosetron in pediatric patients: A single-center, retrospective evaluation of policy and clinical practice guideline discordance.","authors":"Meredith Ames, Priya Patel, L Lee Dupuis, Alicia Koo","doi":"10.1177/10781552241233489","DOIUrl":"10.1177/10781552241233489","url":null,"abstract":"<p><p>IntroductionClinical practice guidelines (CPGs) recommending palonosetron for the prevention and management of chemotherapy-induced nausea and vomiting (CINV) were adapted for use at our institution. Palonosetron was restricted for use in patients experiencing breakthrough CINV and receiving highly emetogenic chemotherapy (HEC) or undergoing stem cell transplant conditioning and in patients with refractory CINV receiving HEC. Given the significant cost of palonosetron, we aimed to determine the proportion of chemotherapy blocks where palonosetron use was discordant with the institutional policy or source CPG.MethodsA retrospective review of the health records of patients who received palonosetron between 1 July 2019 and 30 June 2020 was undertaken. Details of palonosetron use, antiemetic regimen and the date and time of each vomit during the acute and delayed phases were collected for each chemotherapy block where palonosetron was given. Discordance with the institutional policy and the source CPG was determined by assessing the indication for palonosetron and the dose. In the subset of chemotherapy blocks where information regarding vomiting episodes was available, the extent of acute phase chemotherapy-induced vomiting (CIV) control was reported.ResultsFour hundred thirty-eight chemotherapy blocks, representing 122 patients (mean age 9 years), receiving 595 palonosetron doses were included. Palonosetron use was discordant with institutional policy during most (72%; 314/438) of the chemotherapy blocks analyzed. However, palonosetron use was concordant with the source CPG during most chemotherapy blocks (74%; 326/438). Complete CIV control during the acute phase was observed in 66% (195/295) of chemotherapy blocks where palonosetron was given, irrespective of concomitant antiemetics administered.ConclusionThe majority of palonosetron use at our institution was discordant with institutional policy, but concordant with the source CPG. Our institutional policy has since been updated to be more aligned with the source CPG.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"251-255"},"PeriodicalIF":1.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11898370/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139996535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of second-generation Bruton's tyrosine kinase inhibitors for the treatment of mantle cell lymphoma.","authors":"Jessie Lu, Bryan Do, Brian Primeaux","doi":"10.1177/10781552241232331","DOIUrl":"10.1177/10781552241232331","url":null,"abstract":"<p><p>IntroductionSecond-generation Bruton's tyrosine kinase (BTK) inhibitors, acalabrutinib and zanubrutinib, are preferred agents for the treatment of relapsed and/or refractory mantle cell lymphoma (MCL) over first-generation BTK inhibitor, ibrutinib. The comparative safety and efficacy of these two agents have not been studied. Currently, the decision between using one second-generation BTK inhibitor over the other is largely dependent on provider preference, cost, organ dysfunction, presence of drug-drug interactions, adherence considerations, and theorized differences in safety outcomes due to the lack of head-to-head trials in MCL.MethodsThis retrospective, observational study seeks to provide real-world data on the safety and efficacy of second-generation BTK inhibitors in the setting of relapsed and/or refractory MCL.ResultsThirty-eight patients treated with a second-generation BTK inhibitor were evaluated. Ten percent of patients experienced a select adverse drug event (ADE) in the acalabrutinib group that included hypertension and major hemorrhage with no patients experiencing a select ADE in the zanubrutinib group.ConclusionsResults support historical data that acalabrutinib and zanubrutinib have a more favorable safety profile compared to ibrutinib in MCL.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"230-235"},"PeriodicalIF":1.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11898374/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139735469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world treatment outcomes from a retrospective cohort of patients with acute myeloid leukemia from an urban safety net hospital.","authors":"Joseph P Marshalek, Raisa Epistola, Sarah Tomassetti","doi":"10.1177/10781552231225398","DOIUrl":"10.1177/10781552231225398","url":null,"abstract":"<p><p>IntroductionWhile continual advancements in acute myeloid leukemia have augmented response rates and survival, outcomes in clinical trials may not correlate with real-world practice as trials may underrepresent individuals with comorbidities, decreased performance status, and older age. Additionally, clinical trials may underrepresent certain ethnicities, and disparities based on ethnicity, socioeconomic status, and insurance have been demonstrated in acute myeloid leukemia.MethodsWe performed a retrospective chart review of adult patients with acute myeloid leukemia who were treated at Harbor-UCLA from 2014 to 2022 to examine patient characteristics, management patterns, and outcomes in a safety net hospital setting.ResultsThe median age was 56 years old (range 18-84). In regards to risk stratification, 22%, 33%, and 41% had favorable, intermediate, and adverse risk acute myeloid leukemia, respectively. The most common induction regimens included 7 + 3 (55%), azacitidine (10%), azacitidine + venetoclax (7%), and 7 + 3 + midostaurin (7%). The complete remission rate was 51%. Among patients who received intensive induction chemotherapy, 15% underwent re-induction with a second cycle, 51% received consolidation therapy, and 5% received maintenance therapy with a targeted agent. Overall, 12% of patients received allogeneic stem cell transplant. Median overall survival was 12.2 months, and 5-year overall survival was 18%.ConclusionsSuboptimal response rates and survival in this population may be related to low rates of re-induction and allogeneic transplant in addition to high rates of adverse cytogenetics, secondary acute myeloid leukemia, and supportive care only. Efforts to increase access to clinical trials, novel therapies, and transplants for diverse and underinsured populations are essential.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"182-189"},"PeriodicalIF":1.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11898379/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139697701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Manual versus automated chemotherapy preparation: A retrospective pharmaco-economic analysis.","authors":"Meryem Chennaq, Soumaya El Baraka, Ali Cherif Chefchaouni, Houda Benahmed, Aicha Chaibi, Mohammed-Jaouad Belahcen, Younes Rahali","doi":"10.1177/10781552241230889","DOIUrl":"10.1177/10781552241230889","url":null,"abstract":"<p><p>IntroductionThe National Oncology Institute of Morocco's (NIO) shift to an automated cytotoxic drug preparation system (PHARMODUCT®) has prompted an evaluation of its economic and clinical impacts compared to traditional manual methods.MethodsA retrospective cost-benefit analysis over six months, extrapolated to annual projections, assessed initial investments, labour, equipment, drugs and consumables. Four commonly used chemotherapy drugs were analyzed, with a focus on the cost implications of drug waste in manual preparation versus the efficiency of vial-sharing in automated methods.ResultsThe automated system incurred a higher initial cost $2,934,098.74, but reduced annual drug consumption costs by 19.74% and drug-related expenses by $41,228.27. It also decreased personnel costs by $48,073.35. Despite the upfront investment, the system is projected to break even within two years, with no medication waste due to its vial-sharing capability.ConclusionThe initial higher investment in pharmaceutical automation promises considerable long-term savings and efficiency gains. Despite the study's limited scope and duration, the findings endorse the adoption of automated systems in oncology pharmacy settings for sustainable financial management and improved clinical outcomes.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"210-218"},"PeriodicalIF":1.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139706999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacist interventions in optimising opioid medication therapy in pain management for palliative care patients: A systematic review.","authors":"Rajeev Shrestha, Sunil Shrestha, Ayesha Iqbal, Gizem Gülpınar","doi":"10.1177/10781552241296516","DOIUrl":"https://doi.org/10.1177/10781552241296516","url":null,"abstract":"<p><p>BackgroundOpioid therapy is a critical component in managing pain in palliative care, where pharmacists' specialised expertise is crucial in ensuring quality care for patients. This systematic review aims to document available evidence on pharmacist interventions and their impact on optimising opioid therapy for pain management in palliative care patients.MethodsWe searched Medline (OVID), Embase (OVID), APA PsycINFO and Cochrane Central Register of Controlled Trials (CENTRAL) for relevant articles published from the beginning to 31^st December, 2022. All original studies documenting pharmacists' intervention and impact in optimising patients receiving opioid therapy for their pain management in palliative care settings were included in this review.ResultsThe database and reference search yielded to a total of 7154 studies. Out of these, only 3 studies met the eligibility criteria and were included in this study. These studies were conducted in Korea, Canada and United States. Pharmacists were involved in assessing pain, suggesting medication for pain and other symptom management, providing patient education, counselling and recommendation, assessing patient's medication effects such as adverse effects, drug interaction and duplication, and adjusting medication. Similarly, their involvement showed improvements in pain management, opioid usage and management strategies<b>.</b>ConclusionThis systematic review highlights the important role of pharmacists in optimising opioid medication therapy for pain management in palliative care patients. Their contributions to palliative patient care improve pain outcomes and overall quality of life. Integrating pharmacists into palliative care teams can enhance pain management practices and provide better care for palliative patients. Further studies accompanying the robust methodologies and broader settings will validate the findings of this review.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":"31 2","pages":"282-293"},"PeriodicalIF":1.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143615710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative study of dexamethasone premedication regimens with docetaxel chemotherapy in early HER-2 positive breast cancer: A safety net hospital experience.","authors":"Avery Hager, Shreya Kondle, Amulya Agarwal, Monica Chintapenta, Rochelle Horadam, Navid Sadeghi, Samira Syed","doi":"10.1177/10781552241232692","DOIUrl":"10.1177/10781552241232692","url":null,"abstract":"<p><p>IntroductionDocetaxel can cause fluid retention reactions (FRRs) and hypersensitivity reactions (HSRs). The manufacturer recommends a multi-day oral dexamethasone premedication to prevent these toxicities, but steroid related side effects and regimen compliance remain a concern. This study aimed to determine if modified dexamethasone premedication regimens resulted in differences in HSRs or FRRs to docetaxel. We also examined side effects of dexamethasone and delays in chemotherapy.MethodsA retrospective chart review was conducted on 82 early breast cancer patients treated with docetaxel. Three steroid regimens were examined: IV 20 mg single-dose dexamethasone, or IV 12 mg dexamethasone with either dexamethasone 8 mg BID for three days starting the day before chemotherapy or dexamethasone 4 mg BID for three days following chemotherapy. Adverse effects, delays in chemotherapy, and reasons for delays in chemotherapy were recorded.ResultsThe incidence and severity of FRRs and HSRs was low, with less than 10% incidence of HSRs or FRRs in any group. Delays were most common in the group receiving dexamethasone 8 mg BID for 3 days starting the day before chemotherapy (63.3%) (<i>p</i> < 0.05) and were most commonly due to patient noncompliance (26%).ConclusionA single dose of intravenous dexamethasone alone or followed by lower doses of oral dexamethasone may improve patient compliance and avoid delays in chemotherapy, without an increase in docetaxel toxicity.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"236-244"},"PeriodicalIF":1.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11898369/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139996534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Irinotecan-induced dysarthria and management.","authors":"Dennis Marjoncu, Kerri Jones","doi":"10.1177/10781552251324868","DOIUrl":"https://doi.org/10.1177/10781552251324868","url":null,"abstract":"<p><strong>Background: </strong>Irinotecan is chemotherapeutic agent often used in abdominal cancers such as colorectal and pancreatic cancers. While often associated with non-central nervous system (CNS) adverse effects, in rare cases it may present with paresthesias and dysarthrias. In one case, a patient received an irinotecan-containing regimen (fluorouracil, irinotecan, oxaliplatin) and experienced several neurotoxic effects, which was successfully managed.</p><p><strong>Case report: </strong>A female patient with newly-diagnosed pancreatic cancer was started on fluorouracil, irinotecan, and oxaliplatin (modified FOLFIRINOX). She developed dysarthrias early on in the course. Causality assessment was conducted via the Naranjo criteria, yielding a score of 6, indicating a probable adverse reaction.</p><p><strong>Management & outcome: </strong>Initially managed with steroids and lorazepam, she was eventually given a prophylactic strategy of atropine 0.4 mg and a longer infusion time of 3 h instead of 90 min with as needed lorazepam. This strategy alleviated the dysarthrias and the patient was able to complete 12 cycles of therapy, resulting in a partial response at the end of treatment.</p><p><strong>Discussion: </strong>Prolonging the infusion and giving prophylactic atropine may help to prevent these rare adverse effects of irinotecan.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251324868"},"PeriodicalIF":1.0,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143523772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing antineoplastic drug contamination in South African oncology pharmacies: Workplace and biological monitoring.","authors":"Ruan Botha, Gill Nelson, Paul Sessink, Derk Brouwer","doi":"10.1177/10781552251321150","DOIUrl":"10.1177/10781552251321150","url":null,"abstract":"<p><p>IntroductionAntineoplastic drugs (ADs) are hazardous substances commonly used in medical oncology, posing health risks to pharmacy personnel through occupational exposure. Despite safety guidelines, contamination of surfaces in oncology pharmacies remains prevalent. In this study, we assessed surface contamination and biological uptake of ADs in selected South African oncology pharmacies.MethodsSix pharmacies (three from each of two medical oncology service providers, SP1 and SP2) participated. Surface wipe samples were collected from three areas in each pharmacy (containment-primary engineering control (C-PEC), floor, adjacent surface) before and after decontamination procedures. Nine ADs were quantified, using high-pressure liquid chromatography tandem mass spectrometry (HPLC-MS/MS). 24-h urine samples were collected from six pharmacy personnel. The DeRmal Exposure Assessment Method (DREAM) was used to estimate exposure risks. The results were compared with those from an observational study that assessed compliance with safety protocols in the same six pharmacies.ResultsSurface contamination was higher in SP1 than in SP2 pharmacies, with 5-fluorouracil (5-FU) being the most frequently detected AD. Post-decontamination samples showed a 17.4% reduction in 5-FU contamination, although SP1 pharmacies still had higher post-decontamination concentrations than SP2 pharmacies, especially on floors. Cyclophosphamide and ifosphamide were detected in the urine of two participants from SP1.ConclusionWe demonstrated higher contamination and occupational exposure risks in SP1 than in SP2 pharmacies, indicating a need for strict decontamination protocols and better use of personal protective equipment in the SP1 pharmacies. The SP2 pharmacies may serve as a model for oncology pharmacy safety in South Africa.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251321150"},"PeriodicalIF":1.0,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143483472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Carbon footprint of a chemotherapy production unit within a hospital pharmacy: Time for green pharmacy.","authors":"Manon Chabane, Christine Fagnoni-Legat, Camille Hosotte, Maryline Jehl-Rave, Garance Barbier, Sophie Bonnot-Perrin, Farshid Sadeghipour, Laurent Carrez, Samuel Limat, Marie Kroemer","doi":"10.1177/10781552251318313","DOIUrl":"https://doi.org/10.1177/10781552251318313","url":null,"abstract":"<p><strong>Background: </strong>In the last decade, environmental impact assessment has become a major concern for human activities, which is particularly true for health. The french healthcare sector emits approximately 49 million tons of CO₂ equivalent (CO₂eq) per year, approximately 8% of the total national Green House Gas (GHG) emissions. In this context, assessing the carbon footprint of a resource-consuming unit like the cytotoxic drug production unit (CPU) is essential. The study aimed to assess the carbon footprint of a CPU.</p><p><strong>Methods: </strong>A retrospective study was conducted in a french CPU producing more than 51,000 preparations per year in 2022. Global warming impact of CO₂eq emissions were determined for medicines (using the French monetary Emission Factor), single-use material (using the Base Empreinte^® database), energy of electrical devices, staff transportation and waste.</p><p><strong>Results: </strong>The carbon footprint of the CPU was equal to 18'230.7 tons of CO₂eq. Antineoplastic drugs accounted for more than 18'179 tons of CO₂eq emissions. Excluding the medication part, it was equal to 51.7 tons of CO₂eq. More precisely the distribution of CO₂eq emission sources were staff transportation (35.9%), waste (21.1%), single-use sterile medical devices (18.1%), energy consumption (9.3%), disposable personal protective equipment (8.5%), and solvent bags and bottles (7.1%).</p><p><strong>Conclusion: </strong>This study prompts us to identify the main sources of GHG emissions within a CPU. Areas for improvement to reduce global warming impact might be deprescribing of antineoplastic drugs, staff transport reduction using telecommuting or carpooling and rethinking our production process to reduce waste production.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251318313"},"PeriodicalIF":1.0,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143483476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"BRAF inhibitors with or without MEK inhibitors in advanced BRAF-positive non-small cell lung cancer: A systematic review.","authors":"Animesh Saha, T Raja, Amit Dutt Dwary, Indranil Ghosh, Prabrajya Narayan Mahapatra, Tanmoy Mukhopadhay","doi":"10.1177/10781552251322452","DOIUrl":"https://doi.org/10.1177/10781552251322452","url":null,"abstract":"<p><strong>Objective: </strong>About 1% to 5% of cases of non-small cell lung cancer (NSCLC) have been found to have a BRAF mutation. There is no phase III data, despite the fact that numerous phase II and retrospective studies have demonstrated the efficacy of single agent BRAF inhibition and combination BRAF/MEK inhibition in patient groups that have received treatment and those who have not. Our goal in this systematic review was to provide an overview of the available evidence in this context.</p><p><strong>Data sources: </strong>A thorough search was conducted in the PubMed, Medline, Embase, and Cochrane databases for English-language papers published between January 2000 and December 2023 that had full text accessibility. Independently, one author screened the eligible studies that fit our predetermined requirements. A synthesis of the qualitative data was conducted, and the design and quality of the studies were evaluated.</p><p><strong>Data summary: </strong>There were 2952 articles found using the search method. Twelve publications with a total of 753 patients were included after two rounds of screening. 33-75% was the objective response rate (ORR). 64-100% was the disease control rate (DCR). The time span for the answer varied from 6.4 to 16.7 months. The range of the median progression-free survival (PFS) was 1.2 to 17.5 months. The range of the median overall survival (OS) was 1.7-25.5 months. When comparing studies with single agent BRAF inhibitors to those reporting the results of BRAF plus MEK inhibitors, the response rates, duration of response, and survival were better in the former case. When untreated patients receiving BRAF/MEK inhibitor therapy were compared to previously treated patients, the results were also improved. Hypertension, pyrexia, hyponatremia, neutropenia, dyspnoea, anaemia, abnormal liver function, asthenia, and cutaneous epidermoid carcinoma were among the frequently reported grade ≥3 toxicity.</p><p><strong>Conclusions: </strong>Patients with advanced NSCLC that include a BRAF mutation have demonstrated encouraging clinical outcomes with a manageable safety profile when treated with BRAF inhibitors, either in combination with or without MEK inhibitor therapy. In patients who had not received treatment before, combination treatment produced greater results.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251322452"},"PeriodicalIF":1.0,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}